Dystreptase rectal suppositories (suppositories) 2g N6 - Instructions

Dystreptase

Dystreptase is a rectal suppository produced by Poland.
The active ingredients of the drug are streptodornase and streptokinase. Streptodornase is an enzyme that catalyzes the hydrolytic cleavage of phosphodiester bonds in the DNA backbone, thereby destroying it.

Streptokinase is a metal-containing enzyme secreted by β-hemolytic streptococcus. Used as a cheap and widely available substance for thrombolytic therapy. Belongs to the group of fibrinolytic enzymes. Converts inactive plasminogen into its active form - plasmin.

Dystreptase is an original and one-of-a-kind medicine with a combination of active substances that improves blood circulation in the area of ​​inflammation, reduces swelling, and also dissolves dead cells and pus without affecting living cells.

Chronic prostatitis is the most common urological disease that worsens the quality of life of men and often leads to impaired sexual function and fertility. The difficulties of treating chronic prostatitis are well known. Traditional treatment regimens for prostatitis include antibacterial drugs, anti-inflammatory drugs and agents that improve microcirculation. Recently, enzyme preparations with fibrinolytic and proteolytic activity have become relevant in the complex treatment of chronic prostatitis. The article presents the results of a prospective open randomized controlled clinical study of the effectiveness of the drug "Distreptaza" in the complex therapy of chronic bacterial prostatitis.

Chronic prostatitis (CP) is the most common urological disease in men, often occurring latently and leading to disturbances in sexual function and fertility. According to statistics, prostatitis affects 25-40% of men, usually young and middle-aged men of working age [1, 2, 6]. An increase in the incidence of CP in men in recent decades has been observed in all countries of the world. This is due to the widespread prevalence of sexually transmitted infections, a sedentary lifestyle, the influence of harmful environmental factors, uncontrolled use of drugs, allergenicity of the population and other factors [1, 4]. Clinical immunological analysis of CP allows us to state that this disease is a chronic inflammatory process associated with changes in local and systemic immunity, both cellular and humoral, nonspecific defense factors, with the often developing secondary immunodeficiency state. What is important is the increase in sexually transmitted infections, the increase in the aggressiveness of the flora that saprophytes in the urogenital system, and the increase in the number of microbial strains that are resistant to antibacterial drugs [1, 2, 4, 6].

Clinical manifestations of this disease often acquire medical and social significance. Due to the long relapsing course, the variety of etiological factors and pathogenetic mechanisms for the development of CP, its treatment presents significant difficulties. Most of the currently existing traditional treatment methods do not provide the necessary therapeutic effect and negatively affect the quality of life of many patients.

However, the development of modern medical science has led to the emergence of a number of new principles and methods of treating chronic prostatitis. Each method has its own advantages and disadvantages. At the same time, the use of the principles of evidence-based medicine when developing new methods of treating patients is mandatory. Among modern treatment methods, the most effective, according to the recommendations of the US National Institute of Health (NIH), and meeting the criteria of evidence-based medicine, are antibacterial agents, alpha 1-blockers, nonsteroidal anti-inflammatory drugs (NSAIDs), enzyme therapy, and immunotherapy. Only antibacterial agents, alpha 1-blockers and NSAIDs fully comply with the requirements of evidence-based medicine [1, 4, 7, 8].

Bacterial CP, that is, CP category II (NIH, 1995), is considered as an inflammatory disease of infectious origin with the possible addition of autoimmune disorders, characterized by damage to both parenchymal and interstitial tissue of the prostate gland [1, 2]. Regarding the mechanisms of development of abacterial CP (category III), comprehensive and reliable information has not yet been provided. Having begun as an infectious-inflammatory process, CP can subsequently be maintained due to autoimmune mechanisms. Most often, prostatitis develops unnoticed, against the background of congestion in the prostate gland, and proceeds as a sluggish chronic process, in which dilated cavities first form in the depths of the gland due to blockage of the excretory ducts, and then scar-sclerotic changes occur. Attention has been drawn to changes in microcirculation processes in the gland, hormonal and immune status, and disturbances in spermogram parameters in patients with prostatitis [1, 7].

The difficulties of treating CP are well known. Obviously, it should be aimed at eliminating the infectious agent, normalizing the immune status, regression of inflammatory-proliferative changes and restoring the functional activity of the prostate. Particular attention in the complex therapy of CP is paid to improving microcirculation in the prostate gland and blood circulation in the pelvis [1, 2]. To restore blood circulation in the pelvis and microcirculation in the prostate in patients with CP, the use of enzyme preparations with fibrinolytic activity is pathogenetically justified. In order to inhibit the development and achieve regression of the productive component of CP, as well as to prevent the replacement of prostate parenchyma with fibrous tissue, the use of proteolytic enzyme preparations seems to be the most effective [3, 5].

In the modern arsenal of enzyme therapy products, a worthy place is occupied by the drug “Distreptase”, which is a unique duet of proteolytic (streptodornase) and fibrinolytic (streptokinase) enzymes. One suppository contains 15,000 IU of streptokinase and 1250 IU of streptodornase, as well as excipients. Streptokinase is the strongest currently known activator of the human blood proteolytic enzyme system and is widely used as a basic thrombolytic drug, for example, in the treatment of myocardial infarction with a recommended dose of 1,500,000 IU. One distreptase suppository contains a dose of streptokinase 100 times less, which prevents systemic thrombolytic effects and bleeding when using the drug per rectum. Streptokinase has a fibrinolytic effect due to the activation of the proenzyme plasminogen, which under its influence transforms into its active form - plasmin. The latter transforms the fibrin film into a soluble form, thereby dissolving it and blood clots.

Streptodornase - endonuclease (deoxyribonuclease enzyme) - leads to the destruction of DNA, nucleotides and nucleosides, as a result of which the “bridges” of nucleoproteins of dead and coagulated cells dissolve, the resorption of damaged cells and oligoproteins is facilitated, phagocytosis is activated, but does not affect the structure and function of living ones healthy cells. In the presence of streptokinase and streptodornase, the concentration of phagocytes increases significantly, their mobility improves, and the percentage of completed phagocytosis increases. Thus, the use of dystreptase suppositories leads to rapid lysis of leukocyte masses, improvement of blood circulation and microcirculation in the inflammation site, increase in the concentration of antibacterial and other drugs in the inflammation site, rapid elimination of infiltration, edema and clinical manifestations of inflammation, prevention of the development of sclerotic processes [5].

In connection with the above, it seems very interesting to study the clinical effectiveness of the drug “Distreptaza” in complex therapy in patients with CP.
For this purpose, a prospective open randomized controlled clinical trial was conducted at the Urology and Nephrology Clinic of BelMAPO, which included 60 patients with clinically confirmed chronic bacterial prostatitis. Key words:
dysreptaza, treatment, chronic prostatitis
Author(s):
Nitkin D. M., Gaponenko A. D., Vilyukha A. I.
Medical institution: Belarusian Medical Academy of Postgraduate Education

Indications

Based on the research results, it was concluded that Distreptase is a safe and effective medicine. It is used to treat the following diseases:

• chronic salpingitis;
• chronic adnexitis;
• chronic salpingoophoritis;
• postoperative infiltrative processes in the pelvis;
• adhesions in the abdominal cavity after surgery or inflammatory diseases;
• follicular ovarian cysts;
• swelling in diseases of the pelvic organs;
• endometritis;
• acute and chronic hemorrhoids;
• abscesses and fistulas in the anus and rectum with extensive inflammation;
• inflammation of the tissue surrounding the rectum;
• purulent caudal (lower spine) cysts.

Dystreptase rectal suppositories (suppositories) 2g N6 - Instructions

Dosage form

Rectal suppositories, 6 pieces per pack.

Compound

1 suppository contains

Active substances: streptokinase 13,500 – 16,500 IU, streptodornase 1250 – 20,000 IU.

Excipients: vitepsol N15, paraffin oil.

Pharmacotherapeutic group

Other hematological drugs. Enzyme preparations.

Pharmacological properties

The drug contains two active substances: streptokinase and streptodornase. Streptokinase is an activator of the proenzyme plasminogen contained in human blood, and under the influence of streptokinase it is converted into plasmin, which has the property of dissolving human blood clots. Streptodornase is an enzyme that has the ability to dissolve sticky masses of nucleoproteins, dead cells or pus without affecting living cells and their physiological functions. The drug facilitates the access of antibiotics or chemotherapeutic agents to the site of inflammation.

Indications for use

- chronic salpingophoritis

— postoperative infiltrative lesions of the pelvic organs

- endometritis

- acute and chronic hemorrhoids

- perirectal abscess and fistula with extensive inflammatory infiltrate

- purulent caudal cysts

Directions for use and doses

Remove the suppository and insert deeply into the rectum.

The dosage depends on the type and degree of intensity of the inflammatory process.

In severe cases of the disease in adults:

• 1 suppository 3 times a day for the first 3 days;
• 1 suppository 2 times a day for the next 3 days;
• 1 suppository 1 time per day for the next 3 days.

For mild to moderate severity of the disease in adults:

• 1 suppository 2 times a day for 3 days;
• 1 suppository 1 time per day for the next 4 days,
• or 1 suppository 2 times a day for 2 days.

On average, 8–18 suppositories are used per course of treatment.

The average duration of treatment is 7 - 10 days.

Side effects

Sometimes

- allergic reactions

- increase in body temperature

- tendency to bleed

If any atypical reactions occur, be sure to consult your doctor about the possibility of continuing to use the drug!

Contraindications

- hypersensitivity to any component of the drug

— early period after operations on the pelvic and rectal organs

- hemorrhagic diathesis

- pregnancy

Drug interactions

Enhances the penetration of antibiotics and chemotherapy drugs into the site of inflammation.

Should not be used simultaneously with anticoagulants, as local bleeding may occur.

If you are taking other medications, be sure to tell your doctor!

special instructions

The drug should not come into contact with a fresh wound or suture, as this can lead to relaxation of the sutures and, as a result, bleeding from the wound.

While being treated with Dystreptaza, do not take any other medications (including those available without a prescription) without first consulting your doctor. Uncontrolled treatment can harm your health.

Use in pediatrics

There is no experience of use in children, because Clinical studies have not been conducted, so the drug is not recommended for use in children and adolescents under 18 years of age.

Pregnancy and lactation

There is no experience of use in pregnant and lactating women, because Clinical studies have not been conducted, so pregnant and lactating women are not recommended to use the drug.

Features of the effect of the drug on the ability to drive a vehicle or potentially dangerous mechanisms

Does not affect.

Overdose

Not identified.

Storage conditions

Store at temperatures from 2o C to 8o C (in the refrigerator).

Do not freeze!

Keep out of the reach of children!

Shelf life

3 years

Do not use after the expiration date stated on the package.

Conditions for dispensing from pharmacies

On prescription.

Contraindications

Increased sensitivity to the composition of the drug.

The medication should not come into contact with a wound covered with fresh scab or with a fresh suture, as this may cause relaxation of the sutures and, as a result, bleeding.

Not used to treat people with bleeding disorders.

Not prescribed for children.

Not used during pregnancy and lactation.

Anticoagulants and calcium supplements can be combined with Distreptase strictly under the supervision of a specialist.

Endometrioid ovarian cyst

An endometrioid ovarian cyst is a pathological cavity formation on the surface of the ovary, which consists of accumulated menstrual blood surrounded by a membrane of endometrial cells. Unlike functional cysts, endometrioid cysts have a completely different mechanism of development and, as a rule, are affected bilaterally. In gynecology, such an ovarian cyst is a manifestation of the genital form of endometriosis.

The Yusupov Clinic widely uses suppositories for endometriosis and ovarian cysts, which have an analgesic effect.

The most commonly used are suppositories containing non-steroidal anti-inflammatory drugs (for example, indomethacin and diclofenac). For intestinal endometriosis, which is accompanied by spastic pain, suppositories containing papaverine or belladonna are used.

For adhesions in the ovaries, for prophylactic and resolving purposes, suppositories consisting of longidase (they are administered either rectally or vaginally) help well.

Popular questions about Dystreptase

What do Distreptase suppositories treat?

Dystreptase is a well-tolerated medication for the complex treatment of pelvic inflammation.

How to use Distreptase suppositories?

After removal from the blister, the suppositories are injected deep into the rectum. The dose and frequency of administration are prescribed by the doctor individually to each patient. This depends on the severity of the disease.

How to take Distreptase correctly?

Dystreptase is a rectal suppository that is inserted into the rectum. The dose and frequency of administration are prescribed by the doctor individually to each patient. This depends on the severity of the disease. Treatment is carried out according to the following scheme: 1 soup. 3 r. per day for the first 3 days; 1 soup each 2 r. per day for the next 3 days; 1 soup each per day for the next 3 days.

When are Distreptase suppositories prescribed?

When treatment with other forms of drugs is inappropriate. Distreptase, entering the intestine, is quickly absorbed by its walls and then enters the blood, providing a rapid effect on the entire body.

Which candles to choose?

Ichthyol suppositories in gynecology for ovarian cysts have an anti-inflammatory and antiseptic effect. The active substance is ichthyol. This substance is black in color and has a pungent odor. It is used rectally after natural bowel cleansing 1-2 times a day, it can also be used vaginally. The positive effect is achieved quickly enough due to good absorption of the substance. Ichthyol suppositories for ovarian cysts have good reviews due to the absence of contraindications and side effects.

Indomethacin for ovarian cysts reduces pain and swelling by blocking enzymes that cause inflammation. Refers to non-steroidal anti-inflammatory drugs. The effectiveness of the drug is achieved at 90%. Taken vaginally 1-2 suppositories per day, quickly absorbed. It is not recommended for patients with diseases of the gastrointestinal tract, liver, allergies, pregnant women and nursing mothers. Side effects include dizziness, drowsiness, abdominal pain, nausea and vomiting.

Diclovit is a non-steroidal anti-inflammatory drug. It is used as an anti-inflammatory drug for the pelvic organs. Administer rectally after defecation or a cleansing enema, 1-2 suppositories per day. It should not be prescribed for allergic reactions, bronchospasms, individual intolerance to the substance, or for pregnant and lactating women. Side effects: migraine, tinnitus, allergic reaction, and in rare cases, swelling of the legs. In case of overdose, confusion, nausea, vomiting, and bleeding may occur. The drug should be used very carefully in combination with other drugs.

In gynecology, longidaza is used for the treatment and prevention of adhesions formed due to the inflammatory process. It has immunomodulatory, antioxidant and slight anti-inflammatory effects. Has good absorption. One suppository is used after a two-day break. It is administered vaginally or rectally, after cleansing the intestines. Contraindicated for patients with cancer, pregnant women, children under 12 years of age, and kidney disease. Side effects manifest themselves in the form of an allergic reaction.

Suppositories with propolis are used as anti-inflammatory, antibacterial, antioxidant, and immunomodulatory agents. Used vaginally or rectally, after cleansing the intestines.

Note!

The description of the drug Distreptase on this page is a simplified author’s version of the apteka911 website, created on the basis of the instructions for use.
Before purchasing or using the drug, you should consult your doctor and read the manufacturer's original instructions (attached to each package of the drug). Information about the drug is provided for informational purposes only and should not be used as a guide to self-medication. Only a doctor can decide to prescribe the drug, as well as determine the dose and methods of its use.

Newspaper “News of Medicine and Pharmacy” 8(242) 2008

Inflammatory diseases of the pelvic organs not only remain leaders in the structure of gynecological diseases, but also have fatal consequences for women’s reproductive health, thereby creating medical, social and economic problems.

The incidence of infertility in women who have suffered one episode of inflammatory diseases of the pelvic organs is about 18%, and after three episodes reaches 50% (Breeding D., 1997, Reyes I., 2006). The main cause of infertility in such cases is adhesions and fibrous changes in the ovaries that form even after a single inflammation. In this regard, increasing attention is being paid to finding optimal ways to solve problems associated with the consequences of inflammation.

Antibacterial, anti-inflammatory, antimycotic and immunomodulating drugs are used to treat chronic inflammatory diseases of the pelvic organs. Enzymes and agents that improve microcirculation are of great importance in the treatment of such patients. For resorption therapy, enzymatic preparations and biostimulants are most often used, the effectiveness of which is insufficient.

In September 2007, a new drug for resorption therapy, Dystreptase, appeared on the Ukrainian pharmaceutical market. A conference organized by Alpen Pharma GmbH, held in Donetsk, in the restaurant of the Victoria Hotel on April 1, 2008, was devoted to the experience of using the drug in obstetric and gynecological practice. The product manager of the company, Victoria Samsonova, spoke about the effect of the drug. The complex drug Distreptase, produced in Poland and used for the treatment of inflammatory diseases of the pelvic organs, appeared on the Ukrainian market in September 2007. It is produced in the form of rectal suppositories, each of which contains an original combination of active substances - streptokinase 15,000 IU and streptodornase 1250 IU, as well as auxiliary substances that facilitate the absorption and entry of the active components into the blood and lymphatic channels of the pelvic organs.

Streptokinase, as a basic thrombolytic drug, is successfully used in surgery and cardiology in the treatment of extrapelvic thrombosis, although its doses are significantly higher. Streptodornase is an endonuclease enzyme. It dissolves the intermolecular bonds of nucleoproteins of dead cells and pus, facilitates the resorption of oligoproteins, activates phagocytosis without affecting the structure and function of healthy cells. The mechanism of action of Distreptase is based on a unique combination of active components of the drug, which causes rapid lysis of necrotic masses, fibrin deposits and blood clots, which leads to the dissolution of adhesions. The drug is recommended from the first days of the inflammatory process, acts on all phases of inflammation and prevents the development of adhesions. The course of treatment is 7–10 days. Dystreptase is a unique, the only drug in Ukraine for absorbable therapy for inflammatory diseases of the pelvic organs in women of any age category, at any period of the disease. The drug is also widely used in proctology, urology and dermatovenerology.

An assessment of the effectiveness of complex therapy for chronic inflammatory diseases of the uterine appendages using the drug Distreptaza was presented in the report of Associate Professor Sergei Viktorovich Kushnir (Institute of Emergency and Reconstructive Surgery of the Academy of Medical Sciences of Ukraine named after V.K. Gusak). Inflammatory diseases of the uterine appendages make up 82% of other inflammatory diseases, 7% of them are complicated forms. The purpose of the study was to determine the effectiveness of the proposed complex therapy for patients with chronic inflammatory disease of the uterine appendages using the drug Distreptaza. 64 patients made up the control group, 70 - the main group. The criteria for assessing the effectiveness of the proposed therapy were a clinical trial questionnaire and quality of life parameters. The questionnaire included a pain scale, data from general and gynecological examinations, general urine analysis, bacterioscopic examination of a smear from the cervical canal and vagina, ultrasound of the uterus and appendages, duration of treatment, complications of the disease. Assessment of the effectiveness of treatment based on quality of life included physical and mental state, social and role functioning, and general subjective perception of one’s health. Analysis of the study led to the conclusion that the use of the drug Distreptaza in the complex treatment of chronic inflammatory diseases of the uterine appendages allows reducing the treatment time for this group of patients, improving the immediate results of treatment, which ultimately affects the quality of life, since it does not force changes in everyday roles and patients' usual social activity.

The report of Associate Professor Elena Nikolaevna Nosenko (Research Institute of Medical Problems of the Family, Department of Obstetrics, Gynecology and Perinatology of the Donetsk National Medical University named after M. Gorky) presented modern tactics for managing functional ovarian cysts in reproductive age. According to various sources, ovarian masses occupy 2nd place in the structure of all tumors of the genital organs, and 2nd–3rd place in the structure of urgent gynecological pathology. Over the past two decades, the incidence of ovarian tumors among gynecological patients has increased from 6–7 to 19–25%. 75–87% of all ovarian masses are benign. In turn, among benign ovarian formations, 75–80% have a cystic structure.

The incidence of functional ovarian cysts is 60–73%. Functional ovarian cysts are of particular interest, since it is precisely with this form of cystic tumor-like formations of the ovaries, the most common in gynecological practice, that it is possible to carry out conservative medical or minimally invasive surgical treatment, including transvaginal needle aspiration drainage with sclerotherapy and cystectomy. Abundant blood supply and tissue looseness of functional ovarian cysts in one third of patients lead to internal hemorrhages into the lumen of the cyst with the formation of a hematoma, accompanied by pain. Functional ovarian cysts with persistence for more than 2 months have practically no receptors for steroid hormones and are insensitive to hormone therapy. Such cysts can develop significant changes in the form of cellular and nuclear polymorphism. Sclerosis develops in the surrounding ovarian tissue due to compression, impaired circulation and trophic processes.

Distreptase was included in the complex therapy of functional ovarian cysts, including hormonal drugs, immunomodulators, a complex of antihomotoxic drugs, 30% sodium thiosulfate solution IV 10 ml every other day No. 10: 3 days, 3 suppositories per day, 3 days, 2 suppositories candles, 3 days, 1 candle. Active follow-up was carried out for 2 months. When using Distreptase, rapid lysis of blood clots was achieved, improvement of blood circulation and microcirculation in the cyst walls, leading to an increase in the concentration of drugs in the cyst wall and ovary, rapid elimination of infiltration and clinical manifestations of inflammation in the ovary, which subsequently prevents the development of adhesions. The absorbable, fibrinolytic and proteolytic effect of Dystreptase is due to the combination of two active substances - streptokinase and streptodornase. Streptokinase activates the proenzyme plasminogen, which turns into plasmin, which dissolves blood clots, that is, it has a fibrinolytic effect. Streptodornase is a deoxyribonuclease enzyme that leads to the destruction of DNA in the intestinal wall, resulting in deep depolymerization, the “bridges” of nucleoproteins of dead cells dissolve, the resorption of dead cells and oligoproteins is facilitated, and phagocytosis is activated. In the presence of streptokinase and streptodornase, the concentration of phagocytes increases significantly, their mobility improves, and the percentage of completed phagocytosis increases, as a result of which we can achieve regression of the cyst. Regression of formation after treatment was observed in 57% of cases. Thus, as a result of the study, it was revealed that the inclusion of Dystreptase in the treatment regimen for functional ovarian cysts reduces the duration of pain by 2.3 times, the time of cyst resorption by 1.5 times, and in the presence of intracavitary hematoma - by 2.6 times.

During surgical treatment, Distreptase was included in the complex of postoperative measures after 7 days according to the same scheme. The drug is highly tolerable and safe to use. Dystreptase is especially indicated after gynecological operations in women planning pregnancy and wishing to preserve reproductive function.

Alpen Pharma GmbH has initiated a clinical multicenter post-marketing study to evaluate the effectiveness, safety and tolerability of Dystreptase in the complex treatment of inflammatory diseases of the pelvic organs, in which doctors from gynecological centers in Kiev, Donetsk, Kharkov, Dnepropetrovsk, Lvov and Odessa are participating. Gynecologists from Donetsk who also took part in this conference are participating in the study: Voronina Olga Vladimirovna, Kalinovskaya Natalia Evgenievna, Kim Tatyana Horimovna, Popandopulo Alla Dmirievna, Borlova Larisa Aleksandrovna, Tretyakova Larisa Anatolyevna, Omelchenko Natalia Aleksandrovna, Kasyanova Natalia Vasilievna, Azokhova Olga Nikolaevna, Ivanova Tatyana Aleksandrovna, Rastorgueva Elena Georgievna, Kuznetsova Ilona Anatolyevna, Grigoryan Armina Yuryevna, Pavlova Evgenia Viktorovna, Pomelnikova Yulia Andreevna, Taran Natalia Andreevna, Kipiani Maya Vitalievna, Portvenko Andrey Vitalievich, Prezdnyakova Adiliya Faridovna , Filatova Yulia Grigorievna, Petrenko Tatyana Gennadievna, Listratenko Olga Petrovna, Khancha Fedor Aleksandrovich, Yudina Andriana Sergeevna, Sigareva Victoria Aleksandrovna, Ostapenko Tatyana Mikhailovna, Pilipets Valentina Andreevna, Kaverina Victoria Alekseevna.

You will get acquainted with the data obtained as a result of the study and reviews of doctors about the use of the drug in the following publications of our publication.

Prepared by Tatyana Brandis

Composition and pharmacological properties

“Distreptaza” suppositories are a combination drug. The main active ingredients of this product are streptodornase and streptokinase, which have special enzymatic characteristics. The combination of these ingredients provides the drug with many specific pharmacological capabilities:

• dissolving blood clots, preventing the occurrence of blood clots;
• splitting proteins contained in plasma and accelerating the process of dissolving clots;
• dissolution of accumulations of keratinized cells and resorption of purulent contents.

You may be interested in: Auscultation of the heart: listening points, technique and results

You may be interested in: Influenza virus: strain, symptoms, treatment and prevention

In combination, the active components of the drug have antithrombotic, absorbable and anti-inflammatory effects.

Each suppository contains 15,000 IU of streptokinase and 1,250 IU of streptodornase. In addition to these ingredients, Distreptaza suppositories include solid fat and mineral oil.

Pharmacological properties of the drug Distreptase

The drug contains two active substances: streptokinase and streptodornase. Streptokinase is an activator of the proenzyme plasminogen contained in human blood, and under the influence of streptokinase it is converted into plasmin, which has the property of dissolving human blood clots. Streptodornase is an enzyme that has the ability to dissolve sticky masses of nucleoproteins, dead cells or pus without affecting living cells and their physiological functions. The drug facilitates the access of antibiotics or chemotherapeutic agents to the site of inflammation.

Side effects

Negative reactions from using the medication can manifest themselves as:

• allergies;
• increased body temperature;
• intensification of existing bleeding or its development.

If such symptoms occur, you should immediately stop using the drug and consult a specialist.

Candles should be stored in the refrigerator until use. The drug does not reduce concentration and does not affect the patient’s performance and control of vehicles and complex mechanisms.

If there are any contraindications to the use of the product, you should definitely consult a specialist.